On Tuesday, Ventas, Inc. (NYSE:VTR)’s shares declined -1.13% to $63.23.
Ventas, Inc. (VTR) said that its Board of Directors declared a regular quarterly dividend of $0.79 per share, payable in cash on June 30, 2015 to stockholders of record on June 5, 2015. The dividend is the second quarterly installment of the Company’s 2015 annual dividend.
Ventas, Inc. is a publicly owned real estate investment trust. The firm engages in investment, administration, financing, and leasing of properties in the healthcare industry. It invests in the real estate markets of the United States and Canada. The firm primarily invests in healthcare-related facilities counting hospitals, skilled nursing facilities, senior housing facilities, medical office buildings, and other healthcare related facilities.
Array Biopharma Inc (NASDAQ:ARRY)’s shares dropped -0.78% to $7.67.
Array Biopharma Inc (ARRY) was showcased at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). At the meeting, preliminary data for the combination of binimetinib and encorafenib from a Phase 1b/2 dose escalation and expansion study in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive were shared during an oral presentation. Results from the study indicate that binimetinib and encorafenib may be safely combined and show encouraging clinical activity comprising with MEK/BRAF inhibitor expectations in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive. In addition, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging in the dose range presently being used in the Phase 3 COLUMBUS trial. Array anticipates updated BRAF melanoma data from the ongoing Phase 2 combination trial (LOGIC-2) of binimetinib and encorafenib followed by the addition of a third targeted agent identified based on genetic testing at the time of progression will be presented to a scientific conference later this year. LOGIC-2 utilizes the same dose of binimetinib and encorafenib presently being studied in the COLUMBUS trial.
Preliminary data from the study also indicate that in combination with binimetinib, encorafenib was tolerated at doses up to 600 mg, twice its single-agent maximum tolerated dose. At the 400/450 mg dose of encorafenib, with few grade 3 / 4 events and an 11 percent incidence of pyrexia and photosensitivity, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials comprise Binimetinib and Encorafenib for the treatment of cancer. Its clinical programs in Phase II clinical trial comprise ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease.
At the end of Tuesday’s trade, Gannett Co., Inc. (NYSE:GCI)‘s shares dipped -1.06% to $35.31.
Gannett Co., Inc. (GCI) declared that its Board of Directors has approved completion of the formerly declared separation transaction which will create two publicly traded companies: a broadcasting and digital company named TEGNA and new Gannett, which will retain the name Gannett Co., Inc. and will comprise its publishing properties and associated digital assets. Under the terms of the transaction, Gannett shareholders will retain their shares of Gannett (which will be renamed TEGNA) and receive one share of new Gannett for every two shares of Gannett stock they own on the record date of June 22, 2015, and new Gannett shares will start “regular way” trading on June 29, 2015. The spin-off remains subject to the conditions described in the preliminary information statement filed on Form 10 with the U.S. Securities and Exchange Commission.
Gannett Co., Inc. operates as a media and marketing solutions company. It operates through three segments: Broadcasting, Publishing, and Digital. The Broadcasting segment owns and operates 46 television stations that produce local programming, such as news, sports, and entertainment; and associated online sites. The Publishing segment comprises 100 daily publications and digital platforms, counting about 400 non-daily publications in the United States and 125 such titles in the United Kingdom.
Simon Property Group Inc (NYSE:SPG), ended its Tuesday’s trading session with -0.59% loss, and closed at $174.58.
Simon Property Group Inc (SPG) declared that Christian Louboutin will join the luxury lineup at The Galleria, Houston’s premiere shopping and tourist destination.
Christian Louboutin
Christian Louboutin will open their first store in Houston at The Galleria in Fall, 2016. The red-soled shoes of Christian Louboutin have defined glamorous women’s footwear for over 20 years. The Galleria location will be the designer’s 19th U.S. boutique and will carry women’s and men’s shoes, handbags and small leather goods. Louboutin will be located in Galleria I towards Neiman Marcus.
Luxury Transformation Underway
Simon recently declared a $30 million complete renovation of The Galleria’s luxury wing to complement the construction of a new, state-of-the-art flagship Saks Fifth Avenue store slated to open in spring of 2016. The redevelopment project will comprise the addition of 110,000 square-feet of new retail space and the creation of a 14,000 square-foot, architecturally-appealing, free-standing retail building. In total, Simon is investing $250 million to further elevate the shopping experience and ensure that The Galleria remains the destination of choice for shoppers and retailers alike.
Simon Property Group, Inc. is an equity real estate investment trust. The firm invests in the real estate markets across the globe. It engages in investment, ownership, administration, and development of properties. It primarily invests in regional malls, premium outlets, mills, and community/lifestyle centers to create its portfolio. Simon Property Group, Inc. was founded in 1960 and is based in Indianapolis, Indiana, with additional office in New York, New York.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.